A detailed history of Jefferies Group LLC transactions in Cassava Sciences Inc stock. As of the latest transaction made, Jefferies Group LLC holds 34,753 shares of SAVA stock, worth $935,203. This represents 0.01% of its overall portfolio holdings.

Number of Shares
34,753
Previous 59,063 41.16%
Holding current value
$935,203
Previous $1.66 Million 12.47%
% of portfolio
0.01%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Sep 21, 2023

SELL
$16.33 - $51.06 $396,982 - $1.24 Million
-24,310 Reduced 41.16%
34,753 $1.45 Million
Q3 2022

Nov 14, 2022

SELL
$16.33 - $51.06 $396,982 - $1.24 Million
-24,310 Reduced 41.16%
34,753 $1.45 Million
Q2 2022

Sep 21, 2023

BUY
$17.22 - $38.47 $812,749 - $1.82 Million
47,198 Added 397.79%
59,063 $1.66 Million
Q2 2022

Aug 15, 2022

BUY
$17.22 - $38.47 $812,749 - $1.82 Million
47,198 Added 397.79%
59,063 $1.66 Million
Q2 2021

Sep 21, 2023

SELL
$32.15 - $89.72 $36,490 - $101,832
-1,135 Reduced 8.73%
11,865 $1.01 Million
Q2 2021

Aug 16, 2021

SELL
$32.15 - $89.72 $36,490 - $101,832
-1,135 Reduced 8.73%
11,865 $1.01 Million
Q1 2021

Sep 21, 2023

SELL
$7.09 - $87.95 $794,080 - $9.85 Million
-112,000 Reduced 89.6%
13,000 $584,000
Q1 2021

May 14, 2021

SELL
$7.09 - $87.95 $794,080 - $9.85 Million
-112,000 Reduced 89.6%
13,000 $584,000
Q4 2020

Sep 21, 2023

BUY
$6.79 - $12.25 $612,777 - $1.11 Million
90,247 Added 259.68%
125,000 $852,000
Q4 2020

Feb 16, 2021

BUY
$6.79 - $12.25 $169,750 - $306,250
25,000 Added 25.0%
125,000 $853,000
Q2 2020

Aug 14, 2020

BUY
$2.04 - $9.64 $40,800 - $192,800
20,000 Added 25.0%
100,000 $308,000
Q1 2020

May 15, 2020

BUY
$3.26 - $9.65 $32,599 - $96,500
10,000 Added 14.29%
80,000 $329,000
Q4 2019

Feb 13, 2020

BUY
$1.1 - $6.12 $77,000 - $428,400
70,000 New
70,000 $364,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $1.08B
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.